Looks like product mix getting sold is changed for Supriya Life Sciences, as a result they are confident that cyclicality of reduced sales in first half of year would not be same going forward, as guided by management.
They are now targeting Latin America markets and aiming overall 28-30% EBIDTA margins.
20 percent overall revenue growth expectation remains same.
I see that with capacity utilization more than 2.5 times, they should post more than 20 percent, however lets aim for 20 percent growth. Iam happy to take this with both hands.
Overall good improvement in PAT numbers, even though top level was flat.
Anesthetics has good margins
| Subscribe To Our Free Newsletter |
